Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Plasmablastic Lymphoma × daratumumab × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 103 Neoplasms, Plasma Cell 11 Immunoglobulin Light-chain Amyloidosis 11 Recurrence 10 Leukemia, Myeloid, Acute 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasm, Residual 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Paraproteinemias 3 Neoplasms 3 Lymphoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Waldenstrom Macroglobulinemia 2 Smoldering Multiple Myeloma 2 Prostatic Neoplasms 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Leukemia, Plasma Cell 2 Hodgkin Disease 2 Hematologic Diseases 2 Corneal Diseases 2 Blood Protein Disorders 2 Amyloidosis 2 Acute Kidney Injury 2 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Renal Insufficiency 1 Proteostasis Deficiencies 1 Primary Myelofibrosis 1 Plasmacytoma 1

Interventions

prednylidene 1 merphos 1 ixazomib 1 deltacortene 1 daratumumab 1 belantamab mafodotin 1 Vincristine 1 Rituximab 1 Prednisone 1 Methotrexate 1 Hydrocortisone 1 Etoposide 1 Doxorubicin 1 Dexamethasone 1 Cytarabine 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡